Literature DB >> 24134946

Is radiation dose reduction the right answer for HPV-positive head and neck cancer?

Randall J Kimple1, Paul M Harari2.   

Abstract

Patients with head and neck squamous cell carcinoma (HNC) related to human papillomavirus (HPV) represent a growing and distinct patient cohort with unique molecular and epidemiologic characteristics. These patients have markedly improved survival outcomes compared to those with traditional HNC, leading some to advocate for treatment dose reduction. In this article, we review ongoing clinical trials investigating several ways to reduce therapeutic intensity for patients with HPV-positive HNC, discuss the risks and benefits associated with these trials, and summarize the data underlying the advancement of dose reduction trials for patients with HPV-positive HNC.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dose reduction; Head and neck cancer; Human papillomavirus; Radiation

Mesh：

Year:  2013        PMID： 24134946      PMCID： PMC3986346          DOI： 10.1016/j.oraloncology.2013.09.015

Source DB:  PubMed          Journal:  Oral Oncol        ISSN： 1368-8375            Impact factor:   5.337


  47 in total

1.  Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer.

Authors:  Allen M Chen; Bao-Qing Li; Derick H Lau; D Gregory Farwell; Quang Luu; Kerri Stuart; Kathleen Newman; James A Purdy; Srinivasan Vijayakumar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-16       Impact factor: 7.038

2.  Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy.

Authors:  David L Schwartz; Katherine Hutcheson; Denise Barringer; Susan L Tucker; Merrill Kies; F Christopher Holsinger; K Kian Ang; William H Morrison; David I Rosenthal; Adam S Garden; Lei Dong; Jan S Lewin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-18       Impact factor: 7.038

3.  Correlation of a priori DCE-MRI and (1)H-MRS data with molecular markers in neck nodal metastases: Initial analysis.

Authors:  Jacobus F A Jansen; Diane L Carlson; Yonggang Lu; Hilda E Stambuk; Andre L Moreira; Bhuvanesh Singh; Snehal G Patel; Dennis H Kraus; Richard J Wong; Ashok R Shaha; Jatin P Shah; Amita Shukla-Dave
Journal:  Oral Oncol       Date:  2012-02-25       Impact factor: 5.337

4.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States.

Authors:  Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

5.  Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates.

Authors:  Avraham Eisbruch; Hyungjin M Kim; Felix Y Feng; Teresa H Lyden; Marc J Haxer; Mary Feng; Frank P Worden; Carol R Bradford; Mark E Prince; Jeffrey S Moyer; Gregory T Wolf; Douglas B Chepeha; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-17       Impact factor: 7.038

Review 6.  The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome.

Authors:  Pernille Lassen
Journal:  Radiother Oncol       Date:  2010-05-20       Impact factor: 6.280

7.  Association of p16(INK4a) overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue.

Authors:  Stephen L Harris; Leigh B Thorne; William T Seaman; D Neil Hayes; Marion E Couch; Randall J Kimple
Journal:  Head Neck       Date:  2010-12-28       Impact factor: 3.147

8.  Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.

Authors:  Danny Rischin; Richard J Young; Richard Fisher; Stephen B Fox; Quynh-Thu Le; Lester J Peters; Ben Solomon; Jimin Choi; Brian O'Sullivan; Lizbeth M Kenny; Grant A McArthur
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

9.  Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

Authors:  Christopher M Nutting; James P Morden; Kevin J Harrington; Teresa Guerrero Urbano; Shreerang A Bhide; Catharine Clark; Elizabeth A Miles; Aisha B Miah; Kate Newbold; MaryAnne Tanay; Fawzi Adab; Sarah J Jefferies; Christopher Scrase; Beng K Yap; Roger P A'Hern; Mark A Sydenham; Marie Emson; Emma Hall
Journal:  Lancet Oncol       Date:  2011-01-12       Impact factor: 41.316

10.  The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Authors:  Nicole G Chau; Bayardo Perez-Ordonez; Katherine Zhang; Nhu-An Pham; James Ho; Tong Zhang; Olga Ludkovski; Lisa Wang; Eric X Chen; Ming-Sound Tsao; Suzanne Kamel-Reid; Lillian L Siu
Journal:  Head Neck Oncol       Date:  2011-02-27
View more
  17 in total

1.  The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy.

Authors:  Randall J Kimple; Paul M Harari
Journal:  Ann Transl Med       Date:  2015-05

2.  Roles of Ki-67 and p16 as biomarkers for unknown primary head and neck squamous cell carcinoma.

Authors:  Toshiya Maebayashi; Naoya Ishibashi; Takuya Aizawa; Masakuni Sakaguchi; Tsutomu Saito; Jiro Kawamori; Yoshiaki Tanaka; Yukari Hirotani; Taku Homma
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-02-12       Impact factor: 2.503

Review 3.  The Older Adult With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: Knowledge Gaps and Future Direction in Assessment and Treatment.

Authors:  Ronald Maggiore; Zachary S Zumsteg; Karlynn BrintzenhofeSzoc; Kelly M Trevino; Ajeet Gajra; Beatriz Korc-Grodzicki; Joel B Epstein; Stewart M Bond; Ira Parker; Julie A Kish; Barbara A Murphy; Noam A VanderWalde
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-07-15       Impact factor: 7.038

4.  The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): The Memorial Sloan Kettering Cancer Center experience.

Authors:  Adepitan A Owosho; C Jillian Tsai; Ryan S Lee; Haley Freymiller; Arvin Kadempour; Spyridon Varthis; Adi Z Sax; Evan B Rosen; SaeHee K Yom; Joseph Randazzo; Esther Drill; Elyn Riedel; Snehal Patel; Nancy Y Lee; Joseph M Huryn; Cherry L Estilo
Journal:  Oral Oncol       Date:  2016-12-03       Impact factor: 5.337

Review 5.  Modulation of therapeutic sensitivity by human papillomavirus.

Authors:  Adam D Swick; Anirban Chatterjee; Anna-Maria A De Costa; Randall J Kimple
Journal:  Radiother Oncol       Date:  2015-09-10       Impact factor: 6.280

Review 6.  Clinical and scientific impact of human papillomavirus on head and neck cancer.

Authors:  Jeffrey M Friedman; Mark J Stavas; Anthony J Cmelak
Journal:  World J Clin Oncol       Date:  2014-10-10

7.  Expression of DNA-damage response and repair genes after exposure to DNA-damaging agents in isogenic head and neck cells with altered radiosensitivity.

Authors:  Vesna Todorovic; Blaz Groselj; Maja Cemazar; Ajda Prevc; Martina Niksic Zakelj; Primoz Strojan; Gregor Sersa
Journal:  Radiol Oncol       Date:  2022-04-07       Impact factor: 4.214

Review 8.  Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck.

Authors:  Vidya Ajila; Harish Shetty; Subhas Babu; Veena Shetty; Shruthi Hegde
Journal:  J Sex Transm Dis       Date:  2015-09-21

9.  Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.

Authors:  J Bullenkamp; N Raulf; B Ayaz; H Walczak; D Kulms; E Odell; S Thavaraj; M Tavassoli
Journal:  Cell Death Dis       Date:  2014-10-23       Impact factor: 8.469

10.  Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time.

Authors:  Andrew P Stein; Sandeep Saha; Menggang Yu; Randall J Kimple; Paul F Lambert
Journal:  Chem Res Toxicol       Date:  2014-04-02       Impact factor: 3.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.